SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
Abstract
SMARCB1 is a critical component of the BAF complex that is responsible for global chromatin remodeling. Loss of SMARCB1 has been implicated in the initiation of cancers such as malignant rhabdoid tumor (MRT), atypical teratoid rhabdoid tumor (ATRT), and, more recently, renal medullary carcinoma (RMC). These SMARCB1-deficient tumors have remarkably stable genomes, offering unique insights into the epigenetic mechanisms in cancer biology. Given the lack of druggable targets and the high mortality associated with SMARCB1-deficient tumors, a significant research effort has been directed toward understanding the mechanisms of tumor transformation and proliferation. Accumulating evidence suggests that tumorigenicity arises from aberrant enhancer and promoter regulation followed by dysfunctional transcriptional control. In this review, we outline key mechanisms by which loss of SMARCB1 may lead to tumor formation and cover how these mechanisms have been used for the design of targeted therapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 27, 2022
- Source ID
- 10.3390/cancers14153645
Entities
People
- Andrew L Hong
- Garrett W. Cooper
Organizations
- American Cancer Society
- Ian's Friends Foundation
- National Institute of General Medical Sciences
- United States Department of Defense